Is IMMU a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

667 people get IMMU articles and Market Currents by email alert.

Get email alerts on IMMU »

HEADLINES:

Immunomedics' CEO Discusses F3Q13 Results - Earnings Call Transcript
Thu, May 9
Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments

GlobeNewswire (May 8, 2013)
Immunomedics Announces Three New Patent Awards

GlobeNewswire (May 7, 2013)
Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2013 Financial Results

GlobeNewswire (Apr 25, 2013)
Three Biotech Stocks With Low Price But Great Potential
Craig Keolanui • Tue, Apr 16 • 8 Comments
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors

GlobeNewswire (Apr 10, 2013)
Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer

GlobeNewswire (Apr 9, 2013)
Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy

GlobeNewswire (Apr 8, 2013)
Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer and Chronic Pancreatitis

GlobeNewswire (Apr 8, 2013)
3 Radiotherapy Companies That Could Make Big Gains In 2013
Glen S. Woods • Mon, Apr 8 • 3 Comments
Immunomedics' Strengthened Balance Sheet Supports A Compelling Trade Ahead Of Presentations
PropThink • Tue, Apr 2 • 2 Comments
Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities

GlobeNewswire (Apr 1, 2013)
Immunomedics Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research

GlobeNewswire (Apr 1, 2013)
A Quick Look At 8 Biotechs Ready To Gain Momentum
Craig Keolanui • Mon, Mar 11 • 10 Comments
Immunomedics Has A Cheap, Deep And Recently Capitalized Pipeline
PropThink • Fri, Mar 1
Immunomedics Announces Closing of Public Offering and Full Exercise of Overallotment Option by Underwriters

GlobeNewswire (Feb 27, 2013)
Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 25, 2013)
Immunomedics Prices $14.0 Million Public Offering of Common Stock

GlobeNewswire (Feb 22, 2013)
Immunomedics Announces Proposed Public Offering of Common Stock

GlobeNewswire (Feb 21, 2013)
3 Small Cap Radiopharmaceuticals With An Exciting 2013 Ahead
Chemistfrog • Mon, Feb 11 • 4 Comments

To learn more about Seeking Alpha Pro, click here.

Immunomedics' Strengthened Balance Sheet Supports A Compelling Trade Ahead Of Presentations
PropThink • Tue, Apr 2 • 2 Comments
Immunomedics Has A Cheap, Deep And Recently Capitalized Pipeline
PropThink • Fri, Mar 1
Good News for Immunomedics Pipeline
Zacks Investment Research • Mon, Jun 21, 2010 • 1 Comment

Three Biotech Stocks With Low Price But Great Potential
Craig Keolanui • Tue, Apr 16 • 8 Comments
3 Radiotherapy Companies That Could Make Big Gains In 2013
Glen S. Woods • Mon, Apr 8 • 3 Comments
A Quick Look At 8 Biotechs Ready To Gain Momentum
Craig Keolanui • Mon, Mar 11 • 10 Comments
3 Small Cap Radiopharmaceuticals With An Exciting 2013 Ahead
Chemistfrog • Mon, Feb 11 • 4 Comments
3 Small-Cap Biotechs With Zero Debt And Sustainable Revenue
Matt Schilling • Thu, Jan 31 • 3 Comments
Growing Use Of Radiopharmaceuticals For Fighting Cancer Shows Promise
A John Hodge • Mon, Jan 28 • 5 Comments
Targeted Radiation Looks To Create And Grow Revenue
The Swiss Trader • Wed, Dec 5, 2012 • 4 Comments
Cancer Drug Deals Reaching New Heights
Bioassociate Consulting • Tue, Sep 4, 2012 • 1 Comment
Merck Facing Too Much Competition In HIV Drug Push
Freedonia Freelance • Wed, Aug 22, 2012
5 Profit-Generating Biotech Stocks That Analysts Love
ZetaKap • Fri, Aug 17, 2012 • 1 Comment
5 Profitable Healthcare Stocks Preferred By Analysts
ZetaKap • Thu, Aug 16, 2012 • 12 Comments
Investments In Radiotherapy Can Prevent Decay In Your Portfolio
Chemistfrog • Tue, Jul 24, 2012 • 4 Comments
5 Analyst-Backed Healthcare Small Caps Commanding Strong Profits
ZetaKap • Wed, Jul 18, 2012
4 Pharma Companies With Profit Margins Of At Least 24.5%
Matt Schilling • Wed, Jul 18, 2012 • 2 Comments
5 Cash-Heavy Biotechs That Analysts Favor
ZetaKap • Sun, Jul 15, 2012 • 3 Comments
Micro Cap Biotech Stocks Being Accumulated By The World's Largest Money Managers
GuruFundPicks • Wed, Jul 11, 2012 • 9 Comments
6 Biotechnology Stocks Flush With Cash, Stamped As Strong Buys
ZetaKap • Thu, Jun 7, 2012 • 1 Comment
9 Profitable Biotechnology Stocks With Plenty Of Cash
ZetaKap • Tue, May 29, 2012 • 4 Comments
Will Human Genome End Up Blazing A Trail For Others?
Stephen Simpson • Mon, Apr 9, 2012 • 11 Comments
Small Biotech Companies With Big, Promising Pipelines
ScriptVolume • Tue, Jan 31, 2012 • 11 Comments

Immunomedics' CEO Discusses F3Q13 Results - Earnings Call Transcript
Thu, May 9
Immunomedics' CEO Discusses F2Q13 Results - Earnings Call Transcript
Fri, Feb 8 • 1 Comment
Immunomedics' CEO Discusses F1Q13 Results - Earnings Call Transcript
Fri, Nov 9, 2012 • 1 Comment
Immunomedics' CEO Discusses F4Q12 Results - Earnings Call Transcript
Fri, Aug 24, 2012

Immunomedics Announces Third Quarter Fiscal 2013 Results and Clinical Program Developments

GlobeNewswire (May 8, 2013)
Immunomedics Announces Three New Patent Awards

GlobeNewswire (May 7, 2013)
Immunomedics Announces Conference Call and Webcast for Third Quarter Fiscal 2013 Financial Results

GlobeNewswire (Apr 25, 2013)
Immunomedics Develops T-Cell Redirecting Bispecific Antibodies as Potential Therapeutics for Solid and Liquid Tumors

GlobeNewswire (Apr 10, 2013)
Immunomedics Reports First Results of Labetuzumab-SN-38 in Colorectal Cancer

GlobeNewswire (Apr 9, 2013)
Immunomedics Creates Novel Antibody-Cytokine Conjugates for Cancer Therapy

GlobeNewswire (Apr 8, 2013)
Immunomedics Announces Clivatuzumab-Based Blood Test Can Differentiate Between Pancreatic Cancer and Chronic Pancreatitis

GlobeNewswire (Apr 8, 2013)
Immunomedics Settles Finra Arbitration Proceedings Relating to Its Prior Investment in Certain Securities

GlobeNewswire (Apr 1, 2013)
Immunomedics Announces Presentations at the 2013 Annual Meeting of the American Association for Cancer Research

GlobeNewswire (Apr 1, 2013)
Immunomedics Announces Closing of Public Offering and Full Exercise of Overallotment Option by Underwriters

GlobeNewswire (Feb 27, 2013)
Immunomedics to Present at Cowen and Company 33rd Annual Health Care Conference

GlobeNewswire (Feb 25, 2013)
Immunomedics Prices $14.0 Million Public Offering of Common Stock

GlobeNewswire (Feb 22, 2013)
Immunomedics Announces Proposed Public Offering of Common Stock

GlobeNewswire (Feb 21, 2013)
Immunomedics Announces Second Quarter Fiscal 2013 Results and Clinical Program Developments

GlobeNewswire (Feb 7, 2013)
Immunomedics in Collaboration With Algeta to Evaluate Potential of Epratuzumab Conjugated to Alpha-Emitter Thorium-227

GlobeNewswire (Jan 28, 2013)
Immunomedics Announces Conference Call and Webcast for Second Quarter Fiscal 2013 Financial Results

GlobeNewswire (Jan 25, 2013)
Immunomedics Announces U.S. Patent for Hexavalent DOCK-AND-LOCK(TM) Complexes

GlobeNewswire (Jan 8, 2013)
Immunomedics Announces New Patent for Antibodies Targeting CD19

GlobeNewswire (Dec 21, 2012)
Immunomedics Develops New Bispecific Antibodies That Exhibit Potent Anti-Lymphoma Activity

GlobeNewswire (Dec 12, 2012)
Immunomedics Provides Clinical Updates on Subcutaneous Injections of Veltuzumab in Autoimmune Disease and Cancer

GlobeNewswire (Dec 11, 2012)

IMMU vs. ETF Alternatives

Company Description

Immunomedics is a New Jersey-based biopharmaceutical company primarily focused on the development of monoclonal, antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases. We have developed a number of advanced proprietary technologies that allow us to... More

Sector: Healthcare

Industry: Diagnostic Substances

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Wednesday, May 8, 6:53 PM Immunomedics (IMMU): FQ3 EPS of $0.11 beats by $0.21. Revenue of $1.7M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Tuesday, May 7, 9:21 AM Immunomedics (IMMU) looks poised for a strong session after receiving three new patents. The first two relate to the use of conjugates of therapeutic agents for cancer and the combination of radioimmunotherapy and antibody-drug conjugates for improving cancer treatment respectively, while the third patent covers the use of PEGylated alpha interferon created by DNL for autoimmune disease treatment. Shares +4.96% premarket. (PR) Comment! [Healthcare, On the Move]
Tuesday, April 9, 3:24 PM Immunomedics (IMMU +2%) trades up after announcing positive colorectal cancer treatment data earlier today. The drug developer says its proprietary antibody-drug conjugate, labetuzumab-SN-38, appears to be safe and reasonably well tolerated in patients with advanced colorectal cancer. Comment! [Healthcare, On the Move]
Monday, April 8, 1:41 PM Immunomedics (IMMU -2.3%) says recent data presented at the 2013 Annual Meeting of the American Association for Cancer Research shows its Clivatuzumab-based blood test successfully identifies the difference between patients with pancreatic cancer and chronic pancreatitis. The study showed that test, which looks for a positive indication to indentify those who may have cancer, correctly identified two thirds of patients with early stages of the disease. Comment! [Healthcare, On the Move]
Tuesday, April 2, 3:50 PM Immunomedics (IMMU +7.8%), which posted small gains early in the session after announcing a $16.7M arbitration settlement yesterday, rose sharply midday after SA contributor PropThink said the company's cash position now comfortably exceeds 2013's expected cash burn. Tuesday morning's modest gains allowed "investors to make an entrance without paying up for the improved balance sheet," PropThink said. 1 Comment [Healthcare, On the Move]
Tuesday, April 2, 11:50 AM Immunomedics (IMMU +1.2%) moves up today after saying it's reached a $16.7M settlement through securities watchdog FINRA with its former broker Bank of America (BAC). The settlement resolves allegations the drug company had made related to investments in auction rate securities, for which it accused BAML of making false representations or omissions. Comment! [Healthcare, On the Move]
Monday, April 1, 5:29 PM Immunomedics (IMMU) says it will receive a net $16.7M payment after agreeing to settle arbitration proceedings with a broker-dealer. Both the company and the broker are now released from all liabilities associated with the arbitration. Comment! [Healthcare]
Thursday, February 21, 5:43 PM After-hours top gainers, as of 5:15 p.m.: ARUN +14%. WBMD +14%. ACTG +13%. FIRE +11%. BLOX +10%.
After-hours top losers: IMMU -7%. MDAS -6%. VVR -3%. VVUS -3%. PEGA -3%. Comment! [On the Move]
Monday, January 28, 10:40 AM Immunomedics (IMMU +3.3%) says its entered into an agreement with Algeta ASA (ALGZF.PK) for the development of a potential cancer treatment using IMMU's humanized anti-CD22 antibody, epratuzumab. Under the terms of the agreement, IMMU will provide clinical-grade antibody to Algeta, which has rights to evaluate epratuzumab for the treatment of cancer. Algeta will fund all preclinical and clinical development costs up to the end of Phase I testing. 1 Comment [Healthcare, On the Move, Global & FX]
Wednesday, December 12, 2012, 4:08 PM Immunomedics (IMMU) says it's created two new classes of bispecific antibodies as the Dock-And-Lock complexes using the company's patented platform technology. These bispecific antibodies exhibited potent cell killing activity against lymphoma cell lines in vitro, with superior pharmacokinetic profiles and a higher effector functions. Comment! [Healthcare]
Monday, December 10, 2012, 12:50 PM Immunomedics (IMMU -1.7%) reports that preclinical studies of its lead antibody drug candidate, epratuzumab, show the drug to have a distinct way of reducing the immune response of B cells. B cells are responsible for producing antibodies that attack the patient's own body in autoimmune diseases such as lupus. The study results were presented at the 54th Annual Meeting of the American Society of Hematology. Comment! [Healthcare]
Wednesday, December 5, 2012, 1:38 PM Immunomedics (IMMU -3.5%) says it's developed two bispecific, hexavalent antibodies using it's patented technology for targeted therapies of various epithelial cancers. The two antibodies, designated as 1R-(E1)-(E1) and 1R-(15)-(15), were evaluated on three breast cancer cell lines of varying invasiveness, and one pancreatic cancer cell line, and demonstrated improved activity in controlling the spread and invasiveness of cancer cells in both cultures. Comment! [Healthcare]
Thursday, August 23, 2012, 4:20 PM More on Immunomedics (IMMU): FQ4 misses across the board. Revenue was down Y/Y, due primarily to the milestone payment received during the prior year period. Bottom line numbers also suffered from higher than anticipated R&D spending, particularly on further clinical development of its pancreatic cancer drug clivatuzumab. 1 Comment [Healthcare, Earnings]
Thursday, August 23, 2012, 4:04 PM Immunomedics (IMMU): FQ4 EPS of -$0.10 misses by $0.01. Revenue of $1M misses by $0.6M. (PR) Comment! [Earnings, Healthcare]
Tuesday, January 31, 2012, 8:52 AM Shares of Immunomedics (IMMU) push 3.5% higher premarket after the firm nabs a broad-based patent from the USPTO related to antibody-based products for the treatment of cancer. Comment! [Healthcare, On the Move]
Friday, January 20, 2012, 4:29 PM Immunomedics (IMMU -2.2%) finishes the day lower, despite reporting favorable results from the study of its proprietary humanized antibody, clivatuzumab tetraxetan, as a treatment for patients with advanced, inoperable, pancreatic cancer. Comment! [Healthcare, On the Move]

lfpdinc
$IMMU continues to improve
Thu, 12:15 PM
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The_American
BIIB CELG AMGN BMY LLY PFE MRK GILD looking into STEM Cells IMMU CTIC as revolutionary Science and Technology they should be acquiring ESRX
10/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Profit-Generating Biotech Stocks That Analysts Love http://bit.ly/PpNyEQ $BDSI $BSTC $CBPO $IMMU $QCOR @ZetaKap
8/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Profitable Healthcare Stocks Preferred By Analysts http://bit.ly/R3SeBs $BDSI $DUSA $HLF $IMMU $QCOR @ZetaKap
8/16/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Analyst-Backed Healthcare Small Caps Commanding Strong Profits http://bit.ly/MwAu1R $BSTC $IMMU $MLAB $QCOR $TRIB @ZetaKap
7/18/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
5 Cash-Heavy Biotechs That Analysts Favor http://bit.ly/OH4V09 $CRTX $IMMU $OPTR $RGEN $SHP @ZetaKap
7/15/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Biotechnology Stocks Flush With Cash, Stamped As Strong Buys http://bit.ly/NPmZqA $ANIK $BTX $CBPO $IMMU $CRTX $OPTR @ZetaKap
6/7/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
9 Profitable Biotechnology Stocks With Plenty Of Cash http://bit.ly/KXDONj $ALXN $CELG $VRTX $OSIR $QCOR $JAZZ $OMPI $IMMU $SPPI @ZetaKap
5/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
9 Profitable Biotechnology Stocks With Plenty Of Cash http://bit.ly/KXDONj $ALXN $CELG $VRTX $OSIR $QCOR $JAZZ $OMPI $IMMU $SPPI @ZetaKap
5/29/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

lfpdinc
IMMU, this one is gaining momentum
4/24/12
Reply (1)

• !Report Abuse
View all 1 replies
lfpdinc: this is helping: http://on.mktw.net/I9nZXU
4/24/12
• !Report Abuse
Add a reply...

140 characters

LATEST REPLIES

lfpdinc
IMMU, this one is gaining momentum
4/24/12
Reply (1)

• !Report Abuse
View all 1 replies
lfpdinc: this is helping: http://on.mktw.net/I9nZXU
4/24/12
• !Report Abuse
Add a reply...

140 characters

lfpdinc
IMMU promising news on pancreatic cancer http://bit.ly/wRUwoe
1/20/12
Reply (8)

• !Report Abuse
View all 8 replies
lfpdinc: these people can articulate it better than myself: http://bit.ly/x4QmpW
1/20/12
• !Report Abuse
TruffelPig: Many of the biotech companies promise the next great thing in cancer. Few will succeed but I certainly wish them all the best.
1/20/12
• !Report Abuse
Add a reply...

140 characters

IMMU Immunomedics, Inc.

IMMU

Immunomedics, Inc.